Innogest Capital
VC Fund
Milan, Italy
Innogest Capital is a VC fund in Milan focused on Health Care and Medical. Innogest is a venture capital firm founded in 2006 with offices in Turin, Milan, Geneva and San Francisco. It manages investment funds for a total value of about €200 million and it invests in startups mainly in the healthcare and digital sectors mainly in early stage phase. Innogest partners with main local and international research centers andtechnology transfer offices. In the healthcare field, Innogest invests with a focus on medical devices, diagnostics and digital health and with particular attention to therapeutic areas such as cardiovascular, neurology, and oncology. In the digital field, Innogest invests with a focus on foodtech, fintech, fashion-tech and lifestyle verticals
- Total investments:
- 68
- Last investment:
- Lead investor:
- 37%
- Fund size:
- $99M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Innogest Capital invests in
Stages Innogest Capital invests in
Countries Innogest Capital invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $1.1M–$11M
- Series B
- $2.7M–$29M
Investment Focus
Industry
- Health Care 14 (21%)
- Medical 10 (15%)
- Medical Device 9 (13%)
- Biotechnology 7 (10%)
- Mobile 5 (7%)
Stage
- Funding Round 16 (24%)
- Series A 15 (22%)
- Series B 11 (16%)
- Seed 9 (13%)
- Series C 4 (6%)
Country
- Italy 31 (46%)
- United States 5 (7%)
- Spain 3 (4%)
- United Kingdom 2 (3%)
- Israel 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Rick Belluzzo
Partner
|
Partner | Total investments: 2 | Find email | |
Claudio Giuliano
Founder & CEO
|
Founder & CEO | Total investments: 0 | Find email | |
Claudio Rumazza
Founder and CEO
|
Founder and CEO | Total investments: 0 | Find email | |
Elisa Torchia
Back Office Funds Manager
|
Back Office Funds Manager | Total investments: 0 | Find email | |
Giovanni Leo
Partner
|
Partner | Total investments: 5 | Find email | |
| See all 8 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Newronika
|
Newronika restores brain and body functions with innovative technologies. We translate our deep knowledge on biosignal decoding into clinical practice, with the aim of improving treatments, health, and wellness. With our revolutionary brain devices, the patient receives the right stimulation at the right moment, thus becoming able to perform normaldaily activities and improve quality of life. Newronika is the spin-off company of two leading research institutions in Italy, the Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Hospital and the University of Milan. Newronika comprises a multidisciplinary team formed from Neuroscience research groups and involves scientists with expertise in neurophysiology, neurology, biomedical engineering, neuropsychology, bioinformatics, and biotechnologies. | $14.2M / Series B / Feb 13, 2025 | |
BetaGlue Technologies
|
BetaGlue Technologies engage in the research and offers anticancer products. | $10.2M / Seed / Jul 19, 2022 | |
Renovacor
|
Renovacor is a preclinical‑stage biopharmaceutical company focused on developing transformative gene therapy‑based treatments for cardiovascular disease.Renovacor’s lead program is a recombinant adeno-associated virus (AAV)‑based gene therapy for patients suffering from dilated cardiomyopathy (DCM) due to mutations in the Bcl2‑associatedathanogene 3 (BAG3) gene.Dilated cardiomyopathy is a condition affecting over 3 million patients in the US and growing steadily. Many patients develop DCM due to ischemic heart disease. Recently subpopulations have been identified that develop DCM due to mutations in specific genes that have been shown to result in the development of DCM. One of these specific genes is the BAG3 gene. The prevalence of disease‑causing BAG3 haploinsufficiency is estimated at approximately 35,000 individuals in the United States, representing an orphan disease by FDA guidelines. It is estimated a similar number of DCM patients with BAG3 mutations exist in Europe. These patients are typically younger and progress to end-stage heart failure sooner than patients with ischemic heart disease. Currently, DCM patients with a BAG3 mutation are treated with standard of care for heart failure. Despite improvements in pharmacotherapy and care, the five‑year survival of a patient with DCM is only 50%. The development of a BAG3 gene replacement therapy for patients with DCM that carry BAG3 mutations could potentially prevent the progression of disease in this otherwise healthy population of young adults. | $30M / Post-IPO Equity / Sep 03, 2021 | |
GreenBone Ortho
|
GreenBone develops a wood-derived bone implants technology to generate biomimetic – reabsorbable– load bearing implant suitable to address non-union fractures. The idea was conceived and developed by a research group of ISTEC-CNR of Faenza comprised of Andrea Ruffini, Simone Sprio and Anna Tampieri. | $12M / Series B / Apr 13, 2021 | |
Everli
|
Everli is a marketplace for online grocery shopping where customers can choose groceries from a variety of retailers. The company is on a mission to help people achieve peace of mind, simplifying life when shopping for groceries. It offers access to 300,000 products across 70 cities in Italy, France, Polan, and the Czech Republic, while it claimsthat it is the first marketplace to offer same-day grocery delivery services to many small and medium density areas. | $100.3M / Series C / Mar 29, 2021 | |
Medlumics
|
Medlumics is a medical device start-up born in 2009 from a compromise with improving human living standards by means of technology. | $21.8M / Venture - Series Unknown / Feb 10, 2021 | |
Affera, Inc.
|
Affera is a medical technology company dedicated to developing innovative solutions for the treatment of cardiac arrhythmia, a prevalent condition affecting millions of patients worldwide. | $5M / Venture - Series Unknown / Jan 01, 2021 | |
|
Everli
|
Everli is a marketplace for online grocery shopping where customers can choose groceries from a variety of retailers. The company is on a mission to help people achieve peace of mind, simplifying life when shopping for groceries. It offers access to 300,000 products across 70 cities in Italy, France, Polan, and the Czech Republic, while it claimsthat it is the first marketplace to offer same-day grocery delivery services to many small and medium density areas. | $12.2M / Venture - Series Unknown / Jan 31, 2020 | |
Anaconda BioMed
|
Anaconda Biomed, headquartered in Barcelona, Spain, is among the world's most innovative early stage medical technology companies. The company was founded by Dr. Ofir Arad and Dr. Marc Ribó in 2015, and is developing the ANCD BRAIN™, a novel 3rd Generation Stented Aspiration Thrombectomy System for the treatment of Acute Ischemic Stroke (AIS). | $21.9M / Series B / Dec 04, 2019 | |
|
Newronika
|
Newronika restores brain and body functions with innovative technologies. We translate our deep knowledge on biosignal decoding into clinical practice, with the aim of improving treatments, health, and wellness. With our revolutionary brain devices, the patient receives the right stimulation at the right moment, thus becoming able to perform normaldaily activities and improve quality of life. Newronika is the spin-off company of two leading research institutions in Italy, the Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Hospital and the University of Milan. Newronika comprises a multidisciplinary team formed from Neuroscience research groups and involves scientists with expertise in neurophysiology, neurology, biomedical engineering, neuropsychology, bioinformatics, and biotechnologies. | $9.2M / Series A / Sep 25, 2019 | |
| See all 68 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does Innogest Capital invest in?
Innogest Capital invests primarily in Health Care, Medical and Medical Device startups, most often at Funding Round and Series A stage. Most of the 68 investments tracked by Shizune back companies in Italy. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Innogest Capital's check size?
Innogest Capital typically joins rounds of $1.1M–$11M at Series A and $2.7M–$29M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Innogest Capital participates in.
How do I contact Innogest Capital?
Public channels for Innogest Capital include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Innogest Capital?
The team at Innogest Capital includes Rick Belluzzo (Partner), Claudio Giuliano (Founder & CEO) and Claudio Rumazza (Founder and CEO), among 8 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
